ICU Medical Inc
ICUI
Company Profile
Business description
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Contact
951 Calle Amanecer
San ClementeCA92673
USAT: +1 949 366-2183
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
15,000
Stocks News & Analysis
stocks
Is AUB an opportunity after shares plunge 17%?
After a takeover bid was withdrawn shares dropped to below the pre-bid price.
stocks
Attractive ASX listed income opportunity
A high forward distribution yield may entice income investors.
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
Finding value in some of the ASX’s worst recent performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.50 | 11.10 | 0.13% |
| CAC 40 | 8,097.00 | 25.71 | -0.32% |
| DAX 40 | 23,589.44 | 247.35 | -1.04% |
| Dow JONES (US) | 47,289.33 | 427.09 | -0.90% |
| FTSE 100 | 9,702.53 | 17.98 | -0.18% |
| HKSE | 26,024.85 | 8.41 | -0.03% |
| NASDAQ | 23,275.92 | 89.76 | -0.38% |
| Nikkei 225 | 49,343.29 | 40.01 | 0.08% |
| NZX 50 Index | 13,502.77 | 54.28 | 0.40% |
| S&P 500 | 6,812.63 | 36.46 | -0.53% |
| S&P/ASX 200 | 8,579.70 | 14.50 | 0.17% |
| SSE Composite Index | 3,891.89 | 22.12 | -0.57% |